Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy

被引:132
|
作者
Ding, Yingyue [1 ,2 ,3 ]
Wang, Yixin [1 ,2 ,3 ]
Hu, Quanyin [1 ,2 ,3 ]
机构
[1] Univ Wisconsin Madison, Sch Pharm, Pharmaceut Sci Div, Madison, WI 53705 USA
[2] Univ Wisconsin Madison, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI USA
[3] Univ Wisconsin Madison, Sch Pharm, Wisconsin Ctr NanoBioSyst, Madison, WI USA
来源
EXPLORATION | 2022年 / 2卷 / 03期
关键词
cancer; cell; delivery barriers; drug delivery; immunotherapy; FIBROBLAST ACTIVATION PROTEIN; MEMBRANE-COATED NANOPARTICLES; RED-BLOOD-CELLS; CAR-T CELLS; TUMOR MICROENVIRONMENT; DRUG-DELIVERY; EXTRACELLULAR VESICLES; THERAPY; COMBINATION; IMMUNITY;
D O I
10.1002/EXP.20210106
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Immunotherapy strategies that use cell-based delivery systems have sparked much interest in the treatment of malignancies, owing to their high biocompatibility, excellent tumor targeting capability, and unique biofunctionalities in the tumor growth process. A variety of design principles for cell-based immunotherapy, including cell surface decoration, cell membrane coating, cell encapsulation, genetically engineered cell, and cell-derived exosomes, give cancer immunotherapy great potential to improve therapeutic efficacy and reduce adverse effects. However, the treatment efficacy of cell-based delivery methods for immunotherapy is still limited, and practical uses are hampered due to complex physiological and immunological obstacles, such as physical barriers to immune infiltration, immunosuppressive tumor microenvironment, upregulation of immunosuppressive pathways, and metabolic restriction. In this review, we present an overview of the design principles of cell-based delivery systems in cancer immunotherapy to maximize the therapeutic impact, along with anatomical, metabolic, and immunological impediments in using cell-based immunotherapy to treat cancer. Following that, a summary of novel delivery strategies that have been created to overcome these obstacles to cell-based immunotherapeutic delivery systems is provided. Also, the obstacles and prospects of next-step development of cell-based delivery systems for cancer immunotherapy are concluded in the end.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Delivery strategies of cancer immunotherapy: recent advances and future perspectives
    Zhongwei Zhao
    Liyun Zheng
    Weiqian Chen
    Wei Weng
    Jingjing Song
    Jiansong Ji
    Journal of Hematology & Oncology, 12
  • [32] Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy
    Yu, Albert
    Dai, Xiaoyong
    Wang, Zixian
    Chen, Huaqing
    Guo, Bing
    Huang, Laiqiang
    BIOSENSORS-BASEL, 2022, 12 (02):
  • [33] Recent advances in AIE-based platforms for cancer immunotherapy
    Chen, Ziyi
    Li, Xueping
    Liu, Qian
    Li, Wen
    Wang, Tianjiao
    Ade, Ding
    JOURNAL OF CONTROLLED RELEASE, 2024, 376 : 1 - 19
  • [34] Biomimetic Nanoscale Systems for Targeted Delivery in Cancer: Current Advances and Future Prospects
    Singh, Dilpreet
    Poonia, Neelam
    CURRENT DRUG METABOLISM, 2024, 25 (06) : 403 - 415
  • [35] Recent Advances in Perfluorocarbon-Based Delivery Systems for Cancer Theranostics
    Yang, Yueying
    Liu, Yunhu
    Jiang, Yanyan
    MOLECULAR PHARMACEUTICS, 2023, 20 (07) : 3254 - 3277
  • [36] Cell-based drug delivery systems and their in vivo fate
    Yang, Liuxin
    Yang, Yang
    Chen, Yang
    Xu, Yuhong
    Peng, Jinliang
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 187
  • [37] Harnessing Immune Rejuvenation: Advances in Overcoming T Cell Senescence and Exhaustion in Cancer Immunotherapy
    Admasu, Tesfahun Dessale
    Yu, John S.
    AGING CELL, 2025,
  • [38] Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
    Huo, Da
    Jiang, Xiqun
    Hu, Yong
    ADVANCED MATERIALS, 2020, 32 (27)
  • [39] Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles
    Kim, Kwang-Soo
    Kim, Dong-Hwan
    Kim, Dong-Hyun
    PHARMACEUTICS, 2021, 13 (04)
  • [40] Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer
    Ni, Ling
    FRONTIERS IN IMMUNOLOGY, 2022, 13